A2 Biotherapeutics Inc. is recruiting patients for a PHASE1/PHASE2 clinical trial testing CAR-T cell therapy for mesothelioma.
The trial, designated NCT06051695, aims to enroll up to 474 participants at 12 sites, including locations in Arizona, California, Florida.
About the Study
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression.
The main questions this study aims to answer are:
Phase 1: What is the recommended dose that is safe for patients
Phase 2: Does the recommended dose kill solid tumor cells and protect the patient’s healthy cells
Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:
Enrollment and Apheresis in BASECAMP-1 (NCT04981119)
Preconditioning Lymphodepletion (PCLD) Regimen
Tmod CAR T cells at the assigned dose
Treatment Approach
This trial uses genetically engineered T cells that target mesothelin on mesothelioma cells.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: A2 Biotherapeutics Inc.
- Enrollment target: 474
- Status: RECRUITING
Why This Trial Matters
CAR-T cell therapy has revolutionized treatment for blood cancers, and researchers are working to adapt this approach for solid tumors like mesothelioma.
Study Locations
The trial is recruiting at:
- Banner Health, Arizona
- UCSD Moores Cancer Center, California
- UCLA Medical Center, California
- Stanford University, California
- Mayo Clinic, Florida
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening